Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 4

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 4
---
 of profit (loss) of investments accounted for using the equity method      |     |                  |     |      2.7 |     |           |     |     -3.2 |     |          |     |   -5.9 |     |       | ― |     |     |       | ―                         |
| Profit before tax                                                                |     |                  |     |    100.3 |     |           |     |    282.4 |     |          |     |  182.1 |     | 181.5 | % |     |     | 162.4 | %                         |
| Income tax (expenses) benefit                                                    |     |                  |     |     46.9 |     |           |     |    -71.1 |     |          |     | -118.0 |     |       | ― |     |     |       | ―                         |
| Net profit for the period                                                        |     |                  |     |    147.2 |     |           |     |    211.2 |     |          |     |   64.0 |     |  43.5 | % |     |     |  32.0 | %                         |
| Net profit for the period attributable to owners of the Company                  |     |                  |     |    147.1 |     |           |     |    211.1 |     |          |     |   64.0 |     |  43.5 | % |     |     |  32.0 | %                         |

In this section, when comparing results to the same period of the previous fiscal year, the amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. For additional information on CER change, see “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

#### Revenue
Revenue for the nine-month period ended December 31, 2024 was JPY 3,528.2 billion (JPY +315.3 billion and +9.8% AER, +4.5% CER). The increase is attributable to favorable foreign exchange rates and growth from business momentum of Plasma-Derived Therapies (“PDT”), G